Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus

NCT02044848 ↗

Phase 2 Terminated 5 enrolled Novartis Pharmaceuticals

RandomizedParallel-groupDouble-blindTreatment

Summary

This study will assess the safety and efficacy of secukinumab on the preservation of pancreatic beta cells in patients with newly-diagnosed type 1 diabetes mellitus.

Timeline

Start: 2014-02
Primary completion: 2014-09
Completion: 2014-09

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Secukinumab	Monoclonal antibody	—	—

Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus

Summary

Timeline

Drugs

Indications